胃肠道间质瘤孤立性肝转移与肝转移伴肉瘤样变患者的比较。
A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis.
机构信息
Department of Sarcoma Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
出版信息
HPB (Oxford). 2013 Sep;15(9):655-60. doi: 10.1111/hpb.12011. Epub 2012 Dec 27.
OBJECTIVES
This study was conducted to compare overall survival (OS) in patients presenting with isolated hepatic metastases with that of patients with synchronous metastatic disease to the liver and sarcomatosis on a background of gastrointestinal stromal tumours (GISTs).
METHODS
Patients presenting with metastatic GISTs during 1999-2009 were identified. Survival outcomes were compared between groups.
RESULTS
Of the 193 patients with GISTs, 43 patients presented with isolated hepatic metastases and 16 presented with synchronous metastases to the liver and sarcomatosis. Thirteen patients with metastases to the liver and sarcomatosis underwent surgery, and 34 patients with metastatic disease solely to the liver underwent hepatic resection. The proportion of patients treated with preoperative tyrosine kinase inhibitor (TKI) therapy was similar in both groups. Similar OS was observed in both groups (isolated liver metastases group: 40.5 months; liver metastases and sarcomatosis group: 28.7 months; P = 0.620).
CONCLUSIONS
Overall survival in patients with GIST and metastatic disease to the liver and sarcomatosis is similar to that in patients with isolated metastatic liver disease. Although patients with a greater disease burden might be expected to show worse survival, these data do not reflect this assumption.
目的
本研究旨在比较孤立性肝转移和同时性肝转移伴肉瘤病与胃肠道间质瘤（GIST）背景下肝转移的患者的总生存期（OS）。
方法
确定 1999 年至 2009 年间出现转移性 GIST 的患者。比较两组的生存结果。
结果
在 193 例 GIST 患者中，43 例患者出现孤立性肝转移，16 例患者出现同时性肝转移伴肉瘤病。13 例肝转移伴肉瘤病患者接受手术治疗，34 例肝转移患者接受肝切除术。两组患者接受术前酪氨酸激酶抑制剂（TKI）治疗的比例相似。两组患者的 OS 相似（孤立性肝转移组：40.5 个月；肝转移伴肉瘤病组：28.7 个月；P=0.620）。
结论
GIST 伴肝转移和肉瘤病患者的总生存期与单纯肝转移患者相似。尽管预计疾病负担更大的患者生存情况可能更差，但这些数据并未反映出这种假设。
Zotero 插件